HC Wainwright Brokers Lower Earnings Estimates for Savara

Key Points

• HC Wainwright lowered Savara’s Q3 2026 EPS estimate to a loss of $0.16 per share from $0.15, while projecting losses of $0.62 per share for FY2026, $0.37 for FY2027 and $0.06 for FY2028.
• Savara reported a Q2 loss of $0.16 per share, missing the consensus estimate of a $0.14 loss. Analysts nevertheless maintain a “Moderate Buy” consensus rating with an average price target of $10.14.
• Savara shares opened at $5.27, and institutional investors own 87.93% of the company. The clinical-stage biotech is developing Molgradex, a treatment for the rare lung disease autoimmune pulmonary alveolar proteinosis.

Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Savara in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Savara's current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Savara's Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.06) EPS.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02).

Several other equities analysts have also commented on the stock. Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an "outperform" rating and a $11.00 price objective on the stock. Wall Street Zen raised shares of Savara from a "sell" rating to a "hold" rating in a report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $10.14.

Savara Stock Performance

Savara stock opened at $5.27 on Friday. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.09 and a beta of 0.29. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a 50 day simple moving average of $5.65 and a 200-day simple moving average of $5.48. Savara has a 1-year low of $2.68 and a 1-year high of $7.01.

Institutional Trading of Savara

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Savara in the second quarter valued at about $76,966,000. Polar Capital Holdings Plc bought a new position in shares of Savara in the 4th quarter worth about $50,086,000. RTW Investments LP bought a new position in Savara in the fourth quarter worth about $35,893,000. VR Adviser LLC grew its stake in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock worth $20,256,000 after buying an additional 5,626,624 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Savara in the 4th quarter worth about $27,496,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source